Prevalence and treatment outcomes of second primary malignancies in Saudi patients with differentiated thyroid cancers

References

1. ↵
   1. Jemal A,
   2. Siegel R,
   3. Ward E,
   4. Hao Y,
   5. Xu J,
   6. Thun MJ

   (2009) Cancer statistics, 2009. CA Cancer J Clin 59:225–249.

   OpenUrlCrossRefPubMedWeb of Science
2. ↵
   1. Hussain F,
   2. Iqbal S,
   3. Mehmood A,
   4. Bazarbashi S,
   5. ElHassan T,
   6. Chaudhri N

   (2013) Incidence of thyroid cancer in the Kingdom of Saudi Arabia, 2000-2010. Hematol Oncol Stem Cell Ther 6:58–64.

   OpenUrlCrossRefPubMed
3. ↵
   1. Ruggieri M,
   2. Fumarola A,
   3. Straniero A,
   4. Maiuolo A,
   5. Coletta I,
   6. Veltri A,
   7. et al.

   (2008) The estimation of the thyroid volume before surgery--an important prerequisite for minimally invasive thyroidectomy. Langenbecks Arch Surg 393:721–724.

   OpenUrlPubMed
4. ↵
   1. Hsu CH,
   2. Huang CL,
   3. Hsu YH,
   4. Iqbal U,
   5. Nguyen PA,
   6. Jian WS

   (2014) Co-occurrence of second primary malignancy in patients with thyroid cancer. QJM 107:643–648.

   OpenUrlCrossRefPubMed
5. ↵
   1. Sawka AM,
   2. Thabane L,
   3. Parlea L,
   4. Ibrahim-Zada I,
   5. Tsang RW,
   6. Brierley JD,
   7. et al.

   (2009) Second primary malignancy risk after radioactive iodine treatment for thyroid cancer: a systematic review and meta-analysis. Thyroid 19:451–457.

   OpenUrlCrossRefPubMedWeb of Science
6. ↵
   1. Cho YY,
   2. Lim J,
   3. Oh CM,
   4. Ryu J,
   5. Jung KW,
   6. Chung JH,
   7. et al.

   (2015) Elevated risks of subsequent primary malignancies in patients with thyroid cancer: A nationwide, population-based study in Korea. Cancer 121:259–268.

   OpenUrl
7. ↵
   1. Sandeep TC,
   2. Strachan MW,
   3. Reynolds RM,
   4. Brewster DH,
   5. Scélo G,
   6. Pukkala E,
   7. et al.

   (2006) Second primary cancers in thyroid cancer patients: a multinational record linkage study. J Clin Endocrinol Metab 91:1819–1825.

   OpenUrlCrossRefPubMedWeb of Science
8. ↵
   1. Brown AP,
   2. Chen J,
   3. Hitchcock YJ,
   4. Szabo A,
   5. Shrieve DC,
   6. Tward JD

   (2008) The risk of second primary malignancies up to three decades after the treatment of differentiated thyroid cancer. J Clin Endocrinol Metab 93:504–515.

   OpenUrlCrossRefPubMedWeb of Science
9. ↵
   1. Lang BH,
   2. Lo CY,
   3. Wong IO,
   4. Cowling BJ

   (2010) Impact of second primary malignancy on outcomes of differentiated thyroid carcinoma. Surgery 148:1191–1196.

   OpenUrlCrossRefPubMedWeb of Science
10. ↵
    1. Omur O,
    2. Ozcan Z,
    3. Yazici B,
    4. Akgun A,
    5. Oral A,
    6. Ozkilic H

    (2008) Multiple primary tumors in differentiated thyroid carcinoma and relationship to thyroid cancer outcome. Endocr J 55:365–372.

    OpenUrlPubMed
11. ↵
    1. Alghamdi IG,
    2. Hussain II,
    3. Alghamdi MS,
    4. Dohal AA,
    5. Almalki SS,
    6. El-Sheemy MA

    (May 25, 2014) The Incidence Rate of Thyroid Cancer Among Women in Saudi Arabia: An Observational Descriptive Epidemiological Analysis of Data from Saudi Cancer Registry 2001-2008. J Immigr Minor Health, Epub.
12. ↵
    1. Yang YH

    (2014) [A path analysis on factors influencing second primary cancer screening practices in stomach, colon, and breast cancer survivors]. J Korean Acad Nurs 44:139–148, Korean.

    OpenUrl
13. ↵
    1. Lang BH,
    2. Wong IO,
    3. Wong KP,
    4. Cowling BJ,
    5. Wan KY

    (2012) Risk of second primary malignancy in differentiated thyroid carcinoma treated with radioactive iodine therapy. Surgery 151:844–850.

    OpenUrlCrossRefPubMedWeb of Science
14. ↵
    1. Ngeow J,
    2. Stanuch K,
    3. Mester JL,
    4. Barnholtz-Sloan JS,
    5. Eng C

    (2014) Second malignant neoplasms in patients with Cowden syndrome with underlying germline PTEN mutations. J Clin Oncol 32:1818–1824.

    OpenUrlAbstract/FREE Full Text
15. 1. Van Fossen VL,
    2. Wilhelm SM,
    3. Eaton JL,
    4. McHenry CR

    (2013) Association of thyroid, breast and renal cell cancer: a population-based study of the prevalence of second malignancies. Ann Surg Oncol 20:1341–1347.

    OpenUrlCrossRefPubMedWeb of Science
16. ↵
    1. Consorti F,
    2. Di Tanna G,
    3. Milazzo F,
    4. Antonaci A

    (2011) Nulliparity enhances the risk of second primary malignancy of the breast in a cohort of women treated for thyroid cancer. World J Surg Oncol 9:88.

    OpenUrlPubMed
17. ↵
    1. Curtis RE,
    2. Freedman DM,
    3. Ron E,
    4. Ries LAG,
    5. Hacker DG,
    6. Edwards BK,
    7. et al.

    , eds (2006) New Malignancies Among Cancer Survivors: SEER Cancer Registries, 1973-2000 (National Cancer Institute, National Institutes of Health, Bethesda (MD)).
18. ↵
    1. Verkooijen RB,
    2. Smit JW,
    3. Romijn JA,
    4. Stokkel MP

    (2006) The incidence of second primary tumors in thyroid cancer patients is increased, but not related to treatment of thyroid cancer. Eur J Endocrinol 155:801–806.

    OpenUrlAbstract/FREE Full Text
19. ↵
    1. Bhattacharyya N,
    2. Chien W

    (2006) Risk of second primary malignancy after radioactive iodine treatment for differentiated thyroid carcinoma. Ann Otol Rhinol Laryngol 115:607–610.

    OpenUrlCrossRefPubMedWeb of Science